

CivicaScript® launches low-cost treatment to improve walking for people with multiple sclerosis

***Company's fourth launch in 2025 confirms that transparency, collaboration can lower
costs for patients and payers***

Potential savings of \$960/month compared with other generic versions

LEHI, UTAH, AUG. 19, 2025 – CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of generic dalfampridine extended release tablets. Dalfampridine is a potassium channel blocker indicated to improve walking in certain adult patients with multiple sclerosis (MS). Specific information about the use of dalfampridine can be found [here](#).

CivicaScript will offer dalfampridine 10 mg extended-release tablets for sale to pharmacies for \$16 per bottle of 60 tablets – typically a month's supply. CivicaScript recommends that pharmacies charge patients no more than \$37 per bottle (CivicaScript's maximum retail price, or MaxRP™).

CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label.

CivicaScript's MaxRP for dalfampridine **is about \$960 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies.**¹ It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price.

"We've brought four new products to market just this year, saving money for patients and payers while transforming the system along the way," said CivicaScript President Brent J. Eberle. "We've shown that when you create transparency and align all stakeholders to prioritize sustainable low costs, everyone benefits."

A recent report in [The New England Journal of Medicine Catalyst](#) showed that CivicaScript's first product, abiraterone, saved consumers 64% and payers 92% when they switched from other

¹ Compared with 2021 average commercial reimbursement rate for all strengths of dalfampridine. See *Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers*, Federal Trade Commission Second Interim Staff Report, January 2025, at Fig. A2, Table A (pg. 34), available at https://www.ftc.gov/system/files/ftc_gov/pdf/PBM-6b-Second-Interim-Staff-Report.pdf

manufacturers.

CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient.

Dalfampridine was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.

While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place.^{2,3,4}

About CivicaScript

CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A not-for-profit, limited liability company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit [our website](#). CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency.

About dalfampridine

For full prescribing information and patient information, including warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available [here](#). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <http://www.fda.gov/medwatch> or call 1-800-FDA-1088.

MEDIA CONTACT:

Liz Power

liz.power@civicarx.org

+1 860 501 3849

² Dusetzina SB, Besaw RJ, Whitmore CC, et al. Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022. JAMA Netw Open. 2023;6(5):e2314211. doi:10.1001/jamanetworkopen.2023.14211

³ <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/medicine-spending-and-affordability-in-the-us>

⁴ <https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/>